Medical aesthetics company Sientra, Inc., announces the launch the Viality lipoaspirate wash system, which debuted at the recent Beauty Through Science meeting in New York City. This product will be commercially available in the U.S. in the first quarter of 2023.
Fat transfer, a procedure used to relocate fat from one area of the body to another where volume is desired, has increased in popularity in recent years and is used in both breast reconstruction and augmentation procedures, as well as across other body areas such as the buttocks, hands, and face. Despite fat transfer’s growing popularity, physician satisfaction with the currently available fat transfer systems on the market is low, according to Sientra officials.
Developed by researchers at Harvard and Massachusetts General Hospital, Viality is the only fat transfer system with AuraClens, a proprietary cleansing mechanism (lipoaspirate wash) to better retain viable fat leading to more predictable results. In addition, the design enables gentle fat mixing to protect viable fat cells from damage and an absorbent foam layer that removes unwanted fluids and maximizes the concentration of fat. The device also has the capability of processing from 50 to more than 1000cc in a single run.
“As the first-of-its-kind technology, Viality will escalate the standards for fat transfer across the industry,” says board-certified plastic surgeon Brad Calobrace, MD, FACS, who is a principal investigator for the ongoing Viality clinical study. “Viality has brought innovation and intention together in the operating room. The use of this system has revealed a new, extraordinary approach to fat transfer, providing better predictability and results for my patients.”
Studies have shown that Viality produced an average of 94% cell viability and 89% average fat concentration with low processing time and increased volume for reinjection. In addition, the AuraClens concentrating wash was shown in a 20-patient study to improve fat retention by more than 31% compared to saline rinse, Sientra officials say.
“At Sientra ‘good’ has never been enough and we are thrilled to be able to offer plastic surgeons, and their patients, this new innovation that will elevate the standards of plastic surgery and the entire fat transfer category,” says Ron Menezes, president and CEO of Sientra. “We believe that the launch of Viality will significantly increase Sientra’s addressable TAM and add meaningful top-line revenue growth in 2023 as we initially target the breast reconstruction and augmentation market while looking to expand into other body areas.”